Bart C Jacobs

List of Publications by Year
in descending order

114 papers	8,480 citations	71102 41 h-index	48315 88 g-index
115 all docs	115 docs citations	115 times ranked	5637 citing authors

#	Article	IF	Citations
1	Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	30
2	Acute flaccid myelitis and Guillainâ€“BarrÃ© syndrome in children: A comparative study with evaluation of diagnostic criteria. European Journal of Neurology, 2022, 29, 593-604.	3.3	6
3	Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values. Clinical Neurophysiology, 2022, 138, 231-240.	1.5	7
4	International Validation of the Erasmus Guillainâ€“BarrÃ© Syndrome Respiratory Insufficiency Score. Annals of Neurology, 2022, 91, 521-531.	5.3	11
5	Association of mannose-binding lectinÂ2 geneÂpolymorphisms with Guillain-BarrÃ© syndrome. Scientific Reports, 2022, 12, 5791.	3.3	3
6	Guillain-BarrÃ© syndrome: expanding the concept of molecular mimicry. Trends in Immunology, 2022, 43, 296-308.	6.8	24
7	Predicting Outcome in Guillain-BarrÃ© Syndrome. Neurology, 2022, 98, .	1.1	22
8	Epidemiology of chronic inflammatory demyelinating polyradiculoneuropathy in The Netherlands. Journal of the Peripheral Nervous System, 2022, 27, 182-188.	3.1	7
9	Guillain-BarrÃ© syndrome following SARS-CoV-2 vaccination in the UK: a prospective surveillance study. BMJ Neurology Open, 2022, 4, e000309.	1.6	9
10	Neurofilament light chain as biomarker for axonal damage in Guillain-BarrÃ© syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 4-4.	1.9	2
11	COVID-19 vaccine and Guillain-BarrÃ© syndrome: letâ€™s not leap to associations. Brain, 2021, 144, 357-360.	7.6	77
12	Electrophysiology of Guillain-BarrÃ© syndrome in Bangladesh: A prospective study of 312 patients. Clinical Neurophysiology Practice, 2021, 6, 155-163.	1.4	2
13	Guillain-BarrÃ© syndrome during the Zika virus outbreak in Northeast Brazil: An observational cohort study. Journal of the Neurological Sciences, 2021, 420, 117272.	0.6	24
14	Genetic biomarkers for intravenous immunoglobulin response in chronic inflammatory demyelinating polyradiculoneuropathy. European Journal of Neurology, 2021, 28, 1677-1683.	3.3	7
15	Guillain-BarrÃ© Syndrome Outbreak in Peru 2019 Associated With Campylobacter jejuni Infection. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	20
16	Guillain-BarrÃ© Syndrome in Suriname; Clinical Presentation and Identification of Preceding Infections. Frontiers in Neurology, 2021, 12, 635753.	2.4	4
17	Guillainâ€“BarrÃ© syndrome in low-income and middle-income countries: challenges and prospects. Nature Reviews Neurology, 2021, 17, 285-296.	10.1	29
18	Misdiagnosis and diagnostic pitfalls of chronic inflammatory demyelinating polyradiculoneuropathy. European Journal of Neurology, 2021, 28, 2065-2073.	3.3	23

#	Article	IF	Citations
19	Second intravenous immunoglobulin dose in patients with Guillain-BarrÃ© syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 275-283.	10.2	34
20	Intravenous immunoglobulin treatment for mild Guillain-BarrÃ© syndrome: an international observational study. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1080-1088.	1.9	6
21	Antecedent infections in <scp>Guillainâ€BarrÃ©</scp> syndrome in endemic areas of arbovirus transmission: A multinational caseâ€control study. Journal of the Peripheral Nervous System, 2021, 26, 449-460.	3.1	12
22	Guillain-BarrÃ© syndrome after SARS-CoV-2 infection in an international prospective cohort study. Brain, 2021, 144, 3392-3404.	7.6	39
23	Antiglycolipid antibodies in Guillain-BarrÃ© and Fisher syndromes: discovery, current status and future perspective. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 311-318.	1.9	21
24	The legacy of ZikaPLAN: a transnational research consortium addressing Zika. Global Health Action, 2021, 14, 2008139.	1.9	5
25	Original research: Second IVIg course in Guillain-BarrÃ© syndrome with poor prognosis: the non-randomised ISID study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 113-121.	1.9	34
26	Guillain-BarrÃ© syndrome in times of pandemics. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1027-1029.	1.9	7
27	Guillain-BarrÃ© syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1105-1110.	1.9	119
28	Neurological disease in adults with Zika and chikungunya virus infection in Northeast Brazil: a prospective observational study. Lancet Neurology, The, 2020, 19, 826-839.	10.2	68
29	Chemoenzymatic Synthesis of Campylobacter jejuni Lipo-oligosaccharide Core Domains to Examine Guillainâ€“BarrÃ© Syndrome Serum Antibody Specificities. Journal of the American Chemical Society, 2020, 142, 19611-19621.	13.7	27
30	Diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy in clinical practice: A survey among Dutch neurologists. Journal of the Peripheral Nervous System, 2020, 25, 247-255.	3.1	10
31	Boundaries of chronic inflammatory demyelinating polyradiculoneuropathy. Journal of the Peripheral Nervous System, 2020, 25, 4-8.	3.1	12
32	Guillain-BarrÃ© syndrome related to Zika virus infection: AÂsystematic review and meta-analysis of the clinical and electrophysiological phenotype. PLoS Neglected Tropical Diseases, 2020, 14, e0008264.	3.0	41
33	Guillain-BarrÃ© syndrome and chronic inflammatory demyelinating polyradiculoneuropathy after alemtuzumab therapy in kidney transplant recipients. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	11
34	Clinical factors, diagnostic delay, and residual deficits in chronic inflammatory demyelinating polyradiculoneuropathy. Journal of the Peripheral Nervous System, 2019, 24, 253-259.	3.1	15
35	Antecedent infections in Guillainâ€BarrÃ© syndrome: a singleâ€center, prospective study. Annals of Clinical and Translational Neurology, 2019, 6, 2510-2517.	3.7	48
36	Diagnosis and management of Guillainâ€“BarrÃ© syndrome in ten steps. Nature Reviews Neurology, 2019, 15, 671-683.	10.1	463

#	Article	IF	Citations
37	Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis. Neuroepidemiology, 2019, 52, 161-172.	2.3	105
38	Current treatment practice of Guillain-BarrÃ© syndrome. Neurology, 2019, 93, e59-e76.	1.1	57
39	Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurology, The, 2019, 18, 784-794.	10.2	136
40	Efficient design and analysis of randomized controlled trials in rare neurological diseases: An example in Guillain-BarrÃ© syndrome. PLoS ONE, 2019, 14, e0211404.	2.5	3
41	Diagnosis and treatment of Guillainâ€BarrÃ© syndrome during the Zika virus epidemic in Brazil: A national survey study. Journal of the Peripheral Nervous System, 2019, 24, 340-347.	3.1	10
42	International chronic inflammatory demyelinating polyneuropathy outcome study (ICOS): Protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome. Journal of the Peripheral Nervous System, 2019, 24, 34-38.	3.1	11
43	Antibodies to Protein but Not Glycolipid Structures Are Important for Host Defense against Mycoplasma pneumoniae. Infection and Immunity, 2019, 87, .	2.2	9
44	Mycoplasma Pneumoniae and Antibodies against Galactocerebroside in a 9-Year-Old Boy with Encephalitis. Neuropediatrics, 2019, 50, 054-056.	0.6	2
45	<scp>IVI</scp>gâ€induced plasmablasts in patients with Guillainâ€BarrÃ© syndrome. Annals of Clinical and Translational Neurology, 2019, 6, 129-143.	3.7	12
46	Guillainâ€“BarrÃ© syndrome in Denmark: a population-based study on epidemiology, diagnosis and clinical severity. Journal of Neurology, 2019, 266, 440-449.	3.6	27
47	Zika virus infection in the returning traveller: what every neurologist should know. Practical Neurology, 2018, 18, 271-277.	1.1	25
48	Clinical outcome of Guillain-BarrÃ© syndrome after prolonged mechanical ventilation. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 949-954.	1.9	35
49	Guillain-BarrÃ© syndrome following varicella-zoster virus infection. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 511-518.	2.9	36
50	Intrathecal antibody responses to GalC in Guillain-BarrÃ© syndrome triggered by Mycoplasma pneumoniae. Journal of Neuroimmunology, 2018, 314, 13-16.	2.3	12
51	Acute-onset chronic inflammatory demyelinating polyneuropathy after Zika virus infection. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1118-1119.	1.9	9
52	Protocol of a dose response trial of IV immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (DRIP study). Journal of the Peripheral Nervous System, 2018, 23, 5-10.	3.1	8
53	Antibody responses to GalC in severe and complicated childhood Guillainâ€BarrÃ© syndrome. Journal of the Peripheral Nervous System, 2018, 23, 67-69.	3.1	1
54	Regional variation of Guillain-BarrÃ© syndrome. Brain, 2018, 141, 2866-2877.	7.6	190

#	Article	IF	Citations
55	Second IVIg course in Guillainâ€BarrÃ© syndrome patients with poor prognosis (SIDâ€GBS trial): Protocol for a doubleâ€blind randomized, placeboâ€controlled clinical trial. Journal of the Peripheral Nervous System, 2018, 23, 210-215.	3.1	36
56	Reply to: â€œAssociation of hepatitis E virus infection and myasthenia gravis: A pilot studyâ€. Journal of Hepatology, 2018, 68, 1321-1322.	3.7	0
57	Clinical relevance of serum antibodies to GD1b in immuneâ€mediated neuropathies. Journal of the Peripheral Nervous System, 2018, 23, 227-234.	3.1	12
58	Small volume plasma exchange for Guillain-BarrÃ© syndrome in resource-limited settings: a phase II safety and feasibility study. BMJ Open, 2018, 8, e022862.	1.9	22
59	Proximal nerve lesions in early Guillainâ€“BarrÃ© syndrome: implications for pathogenesis and disease classification. Journal of Neurology, 2017, 264, 221-236.	3.6	67
60	Guillain-BarrÃ© syndrome: surveillance and cost of treatment strategies â€“ Authors' reply. Lancet, The, 2017, 389, 253-254.	13.7	11
61	Diagnosis of Guillainâ€“BarrÃ© syndrome in children and validation of the Brighton criteria. Journal of Neurology, 2017, 264, 856-861.	3.6	42
62	Motor nerve excitability after childhood Guillainâ€BarrÃ© syndrome. Journal of the Peripheral Nervous System, 2017, 22, 100-105.	3.1	2
63	International Guillainâ€BarrÃ© Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillainâ€BarrÃ© syndrome. Journal of the Peripheral Nervous System, 2017, 22, 68-76.	3.1	89
64	Could Albumin be a Biomarker to Monitor the Effect of Intravenous Immunoglobulin on Guillain-BarrÃ© Syndrome?â€”Reply. JAMA Neurology, 2017, 74, 872.	9.0	0
65	High mortality from Guillainâ€BarrÃ© syndrome in Bangladesh. Journal of the Peripheral Nervous System, 2017, 22, 121-126.	3.1	29
66	Association of Albumin Levels With Outcome in Intravenous Immunoglobulinâ€“Treated Guillain-BarrÃ© Syndrome. JAMA Neurology, 2017, 74, 189.	9.0	46
67	Treatment dilemmas in Guillain-BarrÃ© syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 346-352.	1.9	68
68	Prediction of disease progression in Miller Fisher andÂoverlap syndromes. Journal of the Peripheral Nervous System, 2017, 22, 446-450.	3.1	7
69	Hepatitis E virus infection and acute non-traumatic neurological injury: A prospective multicentre study. Journal of Hepatology, 2017, 67, 925-932.	3.7	80
70	Tracheostomy or Not: Prediction of Prolonged Mechanical Ventilation in Guillainâ€“BarrÃ© Syndrome. Neurocritical Care, 2017, 26, 6-13.	2.4	52
71	Small volume plasma exchange for Guillain-BarrÃ© syndrome in resource poor settings: a safety and feasibility study. Pilot and Feasibility Studies, 2017, 3, 40.	1.2	13
72	Zika Virus Infection and Guillainâ€“BarrÃ© Syndrome in Three Patients from Suriname. Frontiers in Neurology, 2016, 7, 233.	2.4	17

#	Article	IF	Citations
73	Hospital Admissions, Transfers and Costs of Guillain-BarrÃ© Syndrome. PLoS ONE, 2016, 11, e0143837.	2.5	9
74	Guillain-BarrÃ© syndrome. Lancet, The, 2016, 388, 717-727.	13.7	1,076
75	Mycoplasma pneumoniae triggering the Guillainâ€BarrÃ© syndrome: A caseâ€control study. Annals of Neurology, 2016, 80, 566-580.	5.3	58
76	Microarray screening of Guillain-BarrÃ© syndrome sera for antibodies to glycolipid complexes. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e284.	6.0	25
77	Guillainâ€BarrÃ© syndrome in Bangladesh: validation of Brighton criteria. Journal of the Peripheral Nervous System, 2016, 21, 345-351.	3.1	30
78	Hepatitis E virus and neurological injury. Nature Reviews Neurology, 2016, 12, 77-85.	10.1	198
79	Intrathecal Anti-GalC Antibodies in Bickerstaff Brain Stem Encephalitis. Neuropediatrics, 2015, 46, e1-e1.	0.6	0
80	Severe childhood Guillainâ€BarrÃ© syndrome associated with Mycoplasma pneumoniae infection: a case series. Journal of the Peripheral Nervous System, 2015, 20, 72-78.	3.1	17
81	Skewed Fc Glycosylation Profiles of Anti-proteinase 3 Immunoglobulin G1 Autoantibodies from Granulomatosis with Polyangiitis Patients Show Low Levels of Bisection, Galactosylation, and Sialylation. Journal of Proteome Research, 2015, 14, 1657-1665.	3.7	49
82	Intrathecal Anti-GalC Antibodies in Bickerstaff Brain Stem Encephalitis. Neuropediatrics, 2015, 46, 428-430.	0.6	6
83	Innate <scp>I</scp>mmunity to <scp>C</scp>ampylobacter jejuni in <scp>G</scp>uillainâ€<scp>B</scp>arrÃ© <scp>S</scp>yndrome. Annals of Neurology, 2015, 78, 343-354.	5.3	34
84	Comparison of Fc N-Glycosylation of Pharmaceutical Products of Intravenous Immunoglobulin G. PLoS ONE, 2015, 10, e0139828.	2.5	14
85	Guillain-BarrÃ© Syndrome and Adjuvanted Pandemic Influenza A (H1N1) 2009 Vaccines: A Multinational Self-Controlled Case Series in Europe. PLoS ONE, 2014, 9, e82222.	2.5	53
86	Antibody Responses to Mycoplasma pneumoniae: Role in Pathogenesis and Diagnosis of Encephalitis?. PLoS Pathogens, 2014, 10, e1003983.	4.7	49
87	Prevalence, specificity and functionality of anti-ganglioside antibodies in neuropathy associated with IgM monoclonal gammopathy. Journal of Neuroimmunology, 2014, 268, 89-94.	2.3	23
88	Guillain-BarrÃ© syndrome associated with preceding hepatitis E virus infection. Neurology, 2014, 82, 491-497.	1.1	205
89	Guillainâ€“BarrÃ© syndrome: pathogenesis, diagnosis, treatment and prognosis. Nature Reviews Neurology, 2014, 10, 469-482.	10.1	752
90	Paraparetic Guillain-BarrÃ© syndrome. Neurology, 2014, 82, 1984-1989.	1.1	53

#	Article	IF	Citations
91	Guillain-BarrÃ© Syndrome and Campylobacter Infection. , 2014, , 245-261.		13
92	Mortality in Guillain-BarrÃ© syndrome. Neurology, 2013, 80, 1650-1654.	1.1	177
93	Antibodies to Heteromeric Glycolipid Complexes in Guillain-BarrÃ© Syndrome. PLoS ONE, 2013, 8, e82337.	2.5	60
94	Neuropathophysiological potential of Guillain-BarrÃ© syndrome anti-ganglioside-complex antibodies at mouse motor nerve terminals. Clinical and Experimental Neuroimmunology, 2011, 2, 59-67.	1.0	11
95	High Incidence of Guillain-Barre Syndrome in Children, Bangladesh. Emerging Infectious Diseases, 2011, 17, 1317-1318.	4.3	30
96	Campylobacter jejuni Lipooligosaccharides Modulate Dendritic Cell-Mediated T Cell Polarization in a Sialic Acid Linkage-Dependent Manner. Infection and Immunity, 2011, 79, 2681-2689.	2.2	72
97	Prediction of respiratory insufficiency in Guillainâ€BarrÃ© syndrome. Annals of Neurology, 2010, 67, 781-787.	5.3	224
98	TLR4-Mediated Sensing of Campylobacter jejuni by Dendritic Cells Is Determined by Sialylation. Journal of Immunology, 2010, 185, 748-755.	0.8	72
99	Clinical features, pathogenesis, and treatment of Guillain-BarrÃ© syndrome. Lancet Neurology, The, 2008, 7, 939-950.	10.2	746
100	Subclass IgG to motor gangliosides related to infection and clinical course in Guillainâ€“BarrÃ© syndrome. Journal of Neuroimmunology, 2008, 194, 181-190.	2.3	55
101	Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain, 2008, 131, 1197-1208.	7.6	202
102	Structural Characterization of Campylobacter jejuni Lipooligosaccharide Outer Cores Associated with Guillain-Barrè and Miller Fisher Syndromes. Infection and Immunity, 2007, 75, 1245-1254.	2.2	130
103	Origin of ganglioside complex antibodies in Guillainâ€“BarrÃ© syndrome. Journal of Neuroimmunology, 2007, 188, 69-73.	2.3	39
104	A clinical prognostic scoring system for Guillain-BarrÃ© syndrome. Lancet Neurology, The, 2007, 6, 589-594.	10.2	311
105	Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA. Journal of the Neurological Sciences, 2005, 239, 37-44.	0.6	76
106	The Guillainâ€“BarrÃ© syndrome: a true case of molecular mimicry. Trends in Immunology, 2004, 25, 61-66.	6.8	282
107	Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain, 2003, 126, 2220-2234.	7.6	85
108	A Campylobacter jejuni gene associated with immune-mediated neuropathy. Nature Medicine, 2001, 7, 752-753.	30.7	81

#	Article	IF	Citations
109	Clinical features and response to treatment in Guillain-Barrï¿½ syndrome associated with antibodies to GM1b ganglioside. Annals of Neurology, 2000, 47, 314-321.	5.3	107
110	Clinical features and response to treatment in Guillainâ€BarrÃ© syndrome associated with antibodies to GM1b ganglioside. Annals of Neurology, 2000, 47, 314-321.	5.3	1
111	Miller Fisher anti-GQ1b antibodies: ?-Latrotoxin-like effects on motor end plates. Annals of Neurology, 1999, 45, 189-199.	5.3	203
112	Campylobacter jejuniinfections and anti-GM1 antibodies in guillain-barrÃ© syndrome. Annals of Neurology, 1996, 40, 181-187.	5.3	291
113	Diagnosis and management of Guillainâ€“BarrÃ© syndrome in ten steps. , 0, .		1
114	Population Pharmacokinetic Modelling of Intravenous Immunoglobulin Treatment in Patients with Guillainâ€“BarrÃ© Syndrome. Clinical Pharmacokinetics, 0, , .	3.5	0